ACC/AHA/HFSA Heart Failure Guidelines and Putting Them Into Practice

Published: 17 April 2022

  • Views:

    Views Icon 9259

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

The new 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure were presented at the recent ACC Scientific sessions.

 

In this series of short peer-to-peer discussions, Dr Mikhail Kosiborod, Dr Biykem Bozkurt, and Prof Giuseppe Rosano, discuss the main updates.

This activity was funded via an unrestricted educational grant from AstraZeneca.

Learning Objectives

Following the completion of this programme, physicians will be in a position to:

  • Summarise the main updates to the 2022 ACC heart failure guidelines
  • Discuss data available on the use of SGLT2 inhibitors both in the treatment of HFpEF and across the Heart Failure spectrum
  • Recall how heart failure practice is likely to change in the months ahead

Target Audience

  • Global Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses
  • Pharmacists
  • Other allied HCPs

More from this programme

Part 1

Guideline Directed Medical Therapy in HF

1 session
Guideline Directed Medical Therapy in HF Watch now

Part 2

SGLT-2 Inhibitors Across the Range Of EF

1 session
SGLT-2 Inhibitors Across the Range Of EF Watch now

Part 3

Using Guideline Directed Medical Therapy to Improve Outcomes

1 session
Using Guideline Directed Medical Therapy to Improve Outcomes Watch now

Faculty Biographies

Mikhail Kosiborod

Mikhail Kosiborod

Cardiologist

Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile
Giuseppe Rosano

Giuseppe Rosano

Consultant Cardiologist and Professor of Cardiology (Hon)

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.

His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…

View full profile